Compare Twist Bioscience Corp (TWST) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Zillow Group Inc Class C — how do they compare? Twist Bioscience Corp trades at $159.69 (market cap $10.08B), while Zillow Group Inc Class C trades at $28.79 (market cap $6.59B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Zillow Group Inc Class C for 39 Days on average.
| TWST | Z | |
|---|---|---|
Market Cap | $10.08B | $6.59B |
Volume | 4,229,037 | 9,134,294 |
Sector | Health | Media |
52-Week High | $205.00 | $78.04 |
52-Week Low | $25.45 | $27.13 |
Typical Hold Time | 27 Days | 39 Days |
Enterprise Value | $10.01B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Zillow Group (Z) trades at $27.28, down 1.52% on the day, with technical indicators signaling a bearish trend amid weak moving averages. The company reported revenue of $2.58 billion in 2025, with net income turning positive at $23 million, and recent quarters show mixed earnings performance with two beats and one miss. Analyst sentiment is divided, with a consensus price target of $60.33, while news highlights focus on market competition and AI integration in real estate.
The stock faces headwinds from a challenging housing market and high valuation multiples, but long-term growth potential exists through its transaction platform expansion and AI initiatives. Risks include interest rate sensitivity and competitive pressures, yet institutional analyst coverage remains largely neutral to positive, suggesting cautious optimism for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
